ImmunoPrecise Antibodies (IPA) Stock Statistics & Valuation Metrics

ImmunoPrecise Antibodies has a market cap or net worth of $18.63M. The enterprise value is $15.29M.

ImmunoPrecise Antibodies has 45,765,118 shares outstanding. The number of shares has decreased by -2.65% in one year.

ImmunoPrecise Antibodies’s return on equity (ROE) is -0.80 and return on invested capital (ROIC) is -24.39%.

The current PE Ratio of ImmunoPrecise Antibodies is -1.66. ImmunoPrecise Antibodies’s PEG ratio is 1.78.

In the last 12 months, ImmunoPrecise Antibodies had revenue of 24.52M and earned -27.18M in profits. Earnings per share was -1.06.

In the last 12 months, operating cash flow was -7.17M and capital expenditures -1.39M, giving a free cash flow of -8.56M billion.

ImmunoPrecise Antibodies pays an annual dividend of ―, resulting in a dividend yield of ―

ImmunoPrecise Antibodies upcoming earnings date is Jul 24, 2025, TBA Not Confirmed.

ImmunoPrecise Antibodies as a current ratio of 1.41, with Debt / Equity ratio of 50.26%

In the past 12 months, ImmunoPrecise Antibodies has paid -1.53M in taxes.

ImmunoPrecise Antibodies EV to EBITDA ratio is -2.42, with an EV/FCF ratio of -9.82.

ImmunoPrecise Antibodies has $3.53M in cash and marketable securities with C$14.39M in debt, giving a net cash position of $12.89M billion.

Gross margin is 50.27%, with operating margin of -56.13%, and net profit margin of -110.85%.

The average price target for ImmunoPrecise Antibodies is $4.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy